Novo CagriSema Shows Greater Weight Loss Than Tirzepatide 5 mg in Phase 3 Diabetes Trial

Did CagriSema beat Lilly's tirzepatide?

Yes, on weight loss in this specific trial: CagriSema achieved 12.4% versus 9.1% with tirzepatide 5 mg, while HbA1c reductions were 1.71 and 1.67 percentage points, respectively.

Orbitrum Investor Impact

Why does the result matter for Novo Nordisk?

It strengthens the clinical evidence for CagriSema at the studied 1.0 mg/1.0 mg dose, supporting its potential positioning as a next-generation treatment if approved.

Does this mean CagriSema is better than tirzepatide overall?

No. In the separate REDEFINE 4 obesity trial, CagriSema 2.4 mg/2.4 mg produced 23.0% weight loss versus 25.5% with tirzepatide 15 mg and failed to demonstrate non-inferiority.

Is CagriSema approved?

No. CagriSema remains investigational, and its pending U.S. application is for weight management rather than approval for type 2 diabetes.

Could the result affect Novo Nordisk stock?

The result strengthens one part of the clinical case for a drug Novo is positioning as a successor to Wegovy, but its commercial value still depends on approval, labeling, pricing, uptake and competition with Lilly.

What should Novo Nordisk investors watch next?

The nearest disclosed milestone is an FDA decision expected in the fourth quarter of 2026 on CagriSema's weight-management application, with Novo targeting a launch in early 2027 if approved.